What clinical and diagnostic approaches are used to differentiate the various types of dementia?

Differentiating Types of Dementia: Evidence-Based Clinical Approach

Start with Clinical Phenotype Recognition

The most effective approach to differentiating dementia types begins by identifying the specific clinical phenotype—which cognitive domains are impaired and which are preserved—then confirming with biomarkers when available. 1, 2

Key Clinical Patterns by Dementia Subtype

Alzheimer's Disease (AD):

• Amnestic presentation is most common: prominent difficulty learning and recalling recent information (hippocampal-type memory impairment) plus dysfunction in at least one additional cognitive domain 1, 3
• Insidious onset with gradual progression over months to years 3
• Non-amnestic variants exist (posterior cortical atrophy, logopenic primary progressive aphasia) but are less common 1
• Requires both amyloid-positive AND tau-positive biomarkers for definitive diagnosis—amyloid alone is insufficient because it occurs in other conditions including Lewy body dementia and vascular cognitive impairment 1

Frontotemporal Dementia (FTD):

• Preserved memory is the key distinguishing feature that essentially excludes Alzheimer's disease 4
• Prominent personality and behavioral changes: disinhibition, apathy, loss of empathy, impaired judgment 4
• Language disturbances may be prominent (primary progressive aphasia variants) 4
• Intact motor examination excludes Parkinson's spectrum disorders 4
• Neuroimaging shows focal frontal and/or temporal lobe atrophy, not the generalized symmetric pattern seen in AD 4

Lewy Body Dementia (LBD):

• Visual hallucinations, fluctuating cognition, and parkinsonism are core features 5, 6
• Dopaminergic imaging (DaTscan) can assist with diagnosis 7
• May have amyloid copathology, which is why tau biomarkers help distinguish from AD 1

Vascular Dementia:

• Substantial cerebrovascular disease on imaging with either: stroke temporally linked to cognitive decline, multiple/extensive infarcts, or severe white matter hyperintensity burden 3
• Stepwise or fluctuating decline rather than gradual progression 8
• Mixed vascular-degenerative dementia accounts for approximately 16% of all dementia cases 8

Structured Diagnostic Algorithm

Step 1: Confirm Dementia Diagnosis

• Document that cognitive/behavioral symptoms interfere with work or usual activities (not just mild difficulty) 2, 3
• Establish decline from prior functioning through both patient and knowledgeable informant history 2, 3
• Exclude delirium and major psychiatric disorders 2, 3
• Confirm impairment in at least two of five cognitive domains: memory, executive function, visuospatial abilities, language, or personality/behavior 2, 3

Step 2: Identify the Dominant Clinical Phenotype

• Memory-predominant with gradual onset → Consider AD first 1, 3
• Behavioral/personality changes with preserved memory → Consider FTD 4
• Visual hallucinations + parkinsonism + fluctuating cognition → Consider LBD 5, 6
• Stepwise decline with stroke history or extensive vascular burden → Consider vascular dementia 3, 8

Step 3: Cognitive Assessment Tools

Use domain-specific instruments rather than global screens when differential diagnosis is uncertain 2:

• Addenbrooke's Cognitive Exam-III (ACE-III) provides domain-specific scores useful for distinguishing AD (memory-predominant) from FTD (executive/behavioral-predominant) 2
• Short Test of Mental Status (STMS) is more sensitive than MMSE for distinguishing normal cognition from MCI and predicts later dementia 2
• Formal neuropsychological testing when bedside examination does not yield confident diagnosis 3, 9

Step 4: Neuroimaging Patterns

MRI is superior to CT for detecting focal atrophy patterns 4, 7:

• AD: Medial temporal lobe atrophy (hippocampus), lateral temporal, and medial parietal cortex 3
• FTD: Focal frontal and/or anterior temporal lobe atrophy 4
• Vascular dementia: Multiple infarcts, strategic single infarcts, or severe white matter disease 3, 8
• Use semi-quantitative scales: medial temporal lobe atrophy (MTA) scale, Fazekas scale for white matter changes, global cortical atrophy (GCA) scale 2

Step 5: Biomarker Confirmation for AD

When AD is suspected clinically, biomarkers provide definitive diagnosis 1:

Amyloid biomarkers:

• Low CSF Aβ42 concentration 1, 3
• Positive amyloid PET imaging 1, 3

Tau/neurodegeneration biomarkers:

• Elevated CSF total tau and phosphorylated tau 1, 3
• Reduced FDG uptake on PET in temporoparietal cortex 3
• Disproportionate atrophy on MRI 3

Critical interpretation rule: Both amyloid AND tau positivity are required for AD diagnosis—amyloid alone is non-specific 1

Common Diagnostic Pitfalls

Pitfall 1: Assuming memory impairment equals AD

• FTD, LBD, and vascular dementia can all present with memory complaints, but the pattern differs 4, 5
• In FTD, memory encoding and retrieval are relatively preserved compared to executive dysfunction 4

Pitfall 2: Relying on amyloid biomarkers alone

• Amyloid positivity occurs in cerebral amyloid angiopathy, Lewy body dementia, and age-related changes without dementia 1
• Always require tau positivity in addition to amyloid for AD diagnosis 1

Pitfall 3: Missing mixed pathology

• AD commonly co-occurs with vascular disease or Lewy bodies at autopsy 10, 8
• When clinical features don't fit a single pattern, consider mixed dementia 8

Pitfall 4: Overlooking atypical AD presentations

• Language-predominant (logopenic aphasia), visuospatial-predominant (posterior cortical atrophy), or executive-predominant variants exist, particularly with onset before age 65 1, 3

When to Refer to Specialists

Refer to neurology or geriatrics for 2:

• Atypical presentations (visual or language-dominant variants)
• Uncertain diagnosis requiring comprehensive neuropsychological testing
• Rapidly progressive dementia (decline over weeks to months)
• Prominent psychiatric symptoms that are difficult to differentiate from primary psychiatric disorders, especially when FTD is suspected 4